- Home
- THCH vs MCRB Comparison
THCH vs MCRB Comparison
Compare THCH & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THCH | MCRB |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 78.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | THCH | MCRB |
|---|---|---|
| Price | $1.97 | $7.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 4.9K | ★ 33.2K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.69 | $6.56 |
| 52 Week High | $3.25 | $29.98 |
Technical Indicators
Market Signals| Indicator | THCH | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 41.70 |
| Support Level | $1.74 | $7.33 |
| Resistance Level | $2.27 | $9.53 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 54.55 | 10.39 |
Price Performance
Historical ComparisonAbout THCH TH International Limited Ordinary shares
TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.